Rituximab + Immunotherapy in Follicular Lymphoma

NCT03636503 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
24
Enrollment
OTHER
Sponsor class

Stopped Stopped was stopped prematurely due to drug manufacturer withdrawing supply/funding. Patients already enrolled on study were allowed to continue treatment.

Conditions

Interventions

Sponsor

Dana-Farber Cancer Institute

Collaborators